Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). Clinical research has studied it most carefully for reducing visceral adipose tissue (VAT), the deep fat around organs.
CoreVials tesamorelin is for laboratory research only, not for human or animal use. This page summarizes published research. It is not medical advice.
What problem was the research targeting?
Some people living with HIV develop excess abdominal fat as part of lipodystrophy-related body composition changes. That visceral fat is hard to judge from the scale alone because it sits deeper than subcutaneous fat under the skin.
Tesamorelin trials used imaging endpoints such as VAT area, and later work also looked at liver fat.
What did major trials find?
Pooled Phase 3 style analyses and related randomized trials reported that tesamorelin reduced visceral fat compared with placebo in the studied HIV-associated excess abdominal fat populations.
A separate randomized trial also reported reductions in visceral fat and modest reductions in liver fat over six months in participants with abdominal fat accumulation. Later analyses explored effects in people on modern integrase-inhibitor regimens and again focused on VAT and hepatic fat imaging endpoints.
What stays selective in the data?
A repeated theme is selectivity for visceral fat over simple BMI change. Some reports show VAT and trunk fat moving while subcutaneous fat or overall BMI stay relatively stable. Lean mass sometimes rises.
That pattern matters for interpretation. "Fat loss" in these papers is not always whole-body weight loss.
How does tesamorelin differ from sermorelin?
Both sit in the GHRH family conversation.
- Sermorelin is GHRH(1-29), a shorter fragment with a long diagnostic and pediatric GH literature history.
- Tesamorelin is a modified GHRH analog with a large adult clinical dataset around visceral fat endpoints.
Same broad lane. Different molecule and evidence map.
Research-use reminder
Published clinical results describe regulated medicine research contexts. Catalog research materials are laboratory supplies, not a substitute for clinician-directed care.
References
- Falutz, J., et al. and related Phase 3 tesamorelin visceral fat trial literature in HIV-associated lipodystrophy.
- Stanley, T.L., et al. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. PubMed
- Mangili, A., et al. (2015). Predictors of treatment response to tesamorelin in HIV-infected patients with excess abdominal fat. PLOS ONE. Read the study
